Literature DB >> 27081449

Primary Multiple Cardiac Myxomas in a Patient without the Carney Complex.

Shohei Kataoka1, Masato Otsuka1, Masayuki Goto1, Mitsuru Kahata1, Asako Kumagai1, Koji Inoue1, Hiroshi Koganei1, Kenji Enta1, Yasuhiro Ishii1.   

Abstract

Cardiac tumors are rare, and multiple myxomas are even rarer. The latter phenomenon is mostly associated with the Carney complex, a dominantly inherited disease characterized by multiple primary cardiac myxomas, endocrinopathy, and spotty pigmentation of the skin. We report the rare case of a patient who did not have the Carney complex but had multiple primary cardiac tumors. A 78-year-old woman with a past history of breast cancer was referred to our hospital for further examination of multiple cardiac tumors. Echocardiography showed 4 tumors in the left atrium and left ventricle. We could not diagnose them preoperatively and decided to resect them surgically because they were mobile and could have caused embolism and obstruction. The postoperative pathological findings of all 4 tumors were myxomas, although the patient did not meet the diagnostic criteria of the Carney complex. Therefore, a rare case of multiple primary cardiac myxomas was diagnosed.

Entities:  

Keywords:  Carney complex; Multiple cardiac tumors; Myxoma

Year:  2016        PMID: 27081449      PMCID: PMC4828420          DOI: 10.4250/jcu.2016.24.1.71

Source DB:  PubMed          Journal:  J Cardiovasc Ultrasound        ISSN: 1975-4612


  9 in total

Review 1.  Alterations of cell-mediated immunity following cardiac operations: clinical implications and open questions.

Authors:  A Markewitz; W Lante; A Franke; K Marohl; W D Kuhlmann; C Weinhold
Journal:  Shock       Date:  2001       Impact factor: 3.454

2.  Surgical experience with 77 primary cardiac tumors.

Authors:  Torsten Bossert; Jan F Gummert; Roberto Battellini; Markus Richter; Markus Barten; Thomas Walther; Volkmar Falk; Friedrich Wilhelm Mohr
Journal:  Interact Cardiovasc Thorac Surg       Date:  2005-04-18

3.  Plasma levels of immunoinhibitory cytokines interleukin-10 and transforming growth factor-beta in patients undergoing coronary artery bypass grafting.

Authors:  A Sablotzki; I Welters; N Lehmann; T Menges; G Görlach; M Dehne; G Hempelmann
Journal:  Eur J Cardiothorac Surg       Date:  1997-04       Impact factor: 4.191

4.  Neoplastic heart disease -- the Muenster experience with 108 patients.

Authors:  A Hoffmeier; C Schmid; S Deiters; G Drees; M Rothenburger; T D T Tjan; C Schmidt; A Löher; D Maintz; T Spieker; R M Mesters; H H Scheld
Journal:  Thorac Cardiovasc Surg       Date:  2005-02       Impact factor: 1.827

5.  Should a patient with a treated cancer be offered an open heart operation?

Authors:  C C Canver; C A Marrin; S K Plume; W C Nugent
Journal:  Ann Thorac Surg       Date:  1993-05       Impact factor: 4.330

Review 6.  Atrial myxoma: national incidence, diagnosis and surgical management.

Authors:  S W MacGowan; P Sidhu; T Aherne; D Luke; A E Wood; M C Neligan; E McGovern
Journal:  Ir J Med Sci       Date:  1993-06       Impact factor: 1.568

7.  [Cardiac surgery with extracorporeal circulation in cancer patients: influence on surgical morbidity and mortality and on survival].

Authors:  Yolanda Carrascal; Javier Gualis; Adolfo Arévalo; Enrique Fulquet; Santiago Flórez; Juvenal Rey; José R Echevarría; Salvatore Di Stefano; Luis Fiz
Journal:  Rev Esp Cardiol       Date:  2008-04       Impact factor: 4.753

8.  Differentiation of malignant and benign cardiac tumors using 18F-FDG PET/CT.

Authors:  Kambiz Rahbar; Harald Seifarth; Michael Schäfers; Lars Stegger; Andreas Hoffmeier; Tilmann Spieker; Klaus Tiemann; David Maintz; Hans Heinrich Scheld; Otmar Schober; Matthias Weckesser
Journal:  J Nucl Med       Date:  2012-05-10       Impact factor: 10.057

9.  Cardiopulmonary bypass has a modest association with cancer progression: a retrospective cohort study.

Authors:  Cathy Anne Pinto; Stephen Marcella; David A August; Bart Holland; John B Kostis; Kitaw Demissie
Journal:  BMC Cancer       Date:  2013-11-03       Impact factor: 4.430

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.